Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Mar 18, 2008

DiObex and Camurus Join Forces for Diabetes Treatment

  • DiObex will evaluate Camurus’ delivery technology for its diabetes-related drug. The license agreement will couple DIO-901, an extended-release formulation of low-dose glucagon for the prevention of insulin-induced hypoglycemia in diabetics, with FluidCrystal®, which has a nanoscale-matrice structure.

    DiObex reports that it has successfully completed three Phase I studies using low-dose glucagon infusions in type 1 diabetic patients. The DIO-901 FluidCrystal extended-release formulation is scheduled to enter clinical trials in the second half of this year.

    Terms of the agreement include a signing fee, development milestones, future royalties on product sales, and a share of any potential DiObex sublicensing revenues.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »